当前位置:Public Access >页面
Chinese/English
A single-center, single-arm, open-label, dose escalation study to evaluate the safety & preliminary anti-tumor activity of CD19 allogeneic chimeric antigen receptor T cells (CD19 Allo-CAR-T) for the treatment of patients with relapsed / refractory B cell malignancies
Filter Options
Patient No. Patient Name Patient Gender
Sitting Education Date of enrollment FromTo
       More Options
Patient No Gender Date of enrollment Sitting Creater Operate
2 Man 2018-06-07

Doctor's introduction

caoyaqing
1 Woman 2018-06-15

Doctor's introduction

caoyaqing